Tag Archives: diseases

Chemists recruit anthrax to deliver cancer drugs

“Anthrax toxin is a professional at delivering large enzymes into cells,” says Bradley Pentelute, the Pfizer-Laubauch Career Development Assistant Professor of Chemistry at MIT. “We wondered if we could render anthrax toxin nontoxic, and use it as a platform to deliver antibody drugs into cells.” In a paper appearing in the journal ChemBioChem, Pentelute and colleagues showed that they could use this disarmed version of the anthrax toxin to deliver two proteins known as antibody mimics, which can kill cancer cells by disrupting specific proteins inside the cells…

Better way to track emerging cell therapies using MRIs

In a paper published September 17 in the online journal Magnetic Resonance in Medicine, researchers at the University of California, San Diego School of Medicine, University of Pittsburgh and elsewhere describe the first human tests of using a perfluorocarbon (PFC) tracer in combination with non-invasive magnetic resonance imaging (MRI) to track therapeutic immune cells injected into patients with colorectal cancer. “Initially, we see this technique used for clinical trials that involve tests of new cell therapies,” said first author Eric T. Ahrens, PhD, professor in the Department of Radiology at UC San Diego…

Liposome research meets nanotechnology to improve cancer treatment

While radiotherapy can precisely target just the tumor site, systemic chemotherapy spreads a wide net, sending drugs speeding throughout the entire body in an attempt to kill cancer cells while also killing many healthy cells. Neither of these methods is highly effective when applied alone, therefore separated sessions of chemo and radiotherapy are required when fighting against solid tumors. Reports have shown that ideally, both methods would be employed at the same time…

Dynamic duo takes out cellular trash: Research finds how dead cells are removed from body

Now, Salk scientists have discovered how two critical receptors on these garbage-eating cells identify and engulf dead cells in very different environments, as detailed in Nature Immunology. “To target these receptors as treatments for autoimmune disease and cancer, it’s important to know exactly which receptor is doing what. And this discovery tells us that,” says senior author of the work Greg Lemke, Salk professor of molecular neurobiology and the holder of Salk’s Fran�oise Gilot-Salk Chair. The garbage-disposing cells, known as macrophages, have arrays of receptors on their surface, two of which — called Mer and Axl — are responsible for recognizing dead cells in normal environments and inflamed environments, respectively…

Study identifies gene network behind untreatable leukemia, possible treatment target

Scientists from the Cancer and Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical Center report their results in a study posted online Sept. 4 by Cell Reports. The specific forms of AML and MDS in the current study involve deletions on the arm of a specific chromosome in blood cells (del(5q)…

Repurposing anti-depressant medication to target medulloblastoma

The multi-institutional group, led by scientists at Cancer and Blood Diseases Institute (CBDI) at Cincinnati Children’s Hospital Medical Center, publish their results in the journal’s online edition on Aug. 24. The researchers suggest their laboratory findings in mouse models of the disease could lead to a more targeted and effective molecular therapy that would also reduce the harmful side effects of current treatments, which include chemotherapy, radiation or surgery. “Although current treatments improve survival rates, patients suffer severe side effects and relapse tumors carry mutations that resist treatment,” said lead investigator Q. …

New mouse model points to therapy for liver disease

Development of effective new therapies for preventing or treating NASH has been stymied by limited small animal models for the disease. In a paper published online in Cancer Cell, scientists at the University of California, San Diego School of Medicine describe a novel mouse model that closely resembles human NASH and use it to demonstrate that interference with a key inflammatory protein inhibits both the development of NASH and its progression to liver cancer. “These findings strongly call for clinical testing of relevant drugs in human NASH and its complications,” said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology in UC San Diego’s Laboratory of Gene Regulation and Signal Transduction. “Our research has shown that, at least in this mouse model, chemical compounds that include already clinically approved drugs that inhibit protein aggregation can also be used to prevent NASH caused by a high fat diet.” The increasing prevalence of NAFLD is linked to the nation’s on-going obesity epidemic. …

Tool to better visualize, analyze human genomic data developed

Next-generation sequencing has revolutionized functional genomics. These techniques are key to understanding the molecular mechanisms underlying cell function in healthy and diseased individuals and the development of diseases like cancer. Data from multiple experiments need to be integrated, but the growing number of data sets makes a thorough comparison and analysis of results challenging. …